 Molecular Templates, Inc., MTEM a clinical-stage biopharmaceutical company focused on the discovery and development of the Companys proprietary targeted biologic therapeutics, engineered toxin bodies ETBs, provided a corporate update and outlined expected 2020 milestones. 2019 was a year of growth for MTEM as we advanced our pipeline programs, established a new collaboration outside of oncology with a premier partner, and strengthened our balance sheet with a successful equity financing, said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. 